Quinagolide

Registered South African indications:

• Hyperprolactinaemia

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Renal impairment
• Hepatic impairment
• Pregnancy

Cautions

• Breastfeeding
• Elderly
• Female patients of childbearing age
• History of psychotic episodes
• Parkinson's disease
• May impair ability to drive and operate machinery

Forms avail. in SA and covered in this monograph: tab

Hyperprolactinaemia
- Idiopathic or originating from a prolactin-secreting pituitary microadenoma or macroadenoma, associated with clinical manifestations

• Oral (tab): Day 1-3: 25μg, dly; Day 4-6: 50μg, dly; Day 7 onwards: 75μg, dly; Titrate by 75-150μg/day at intervals of 4 weeks; Maintenance: 75-150μg/day; Max: 900μg/24hrs

Take at bedtime with food

Not established for use in children

Pregnancy

• FDA Pregnancy Category Not Rated (NR)

Breastfeeding

• Caution; not recommended

Renal Impairment

• Contraindicated

Hepatic Impairment

• Contraindicated

Elderly          

• Caution; no information available  

Central Nervous System Disorders

• Headache
• Dizziness
• Fatigue
• Insomnia
• Acute psychosis
• Somnolence
• Compulsive behaviour

Cardiovascular Disorders

• Flushing
• Hypotension
• Orthostatic hypotension 

Respiratory Disorders

• Nasal congestion

Gastrointestinal Disorders

• Nausea and vomiting
• Abdominal pain
• Constipation 
• Diarrhoea

Genitourinary Disorders

• Increased libido
• Hypersexuality

Skin and Subcutaneous Tissue Disorders

• Oedema
• Flushing

No information available

• Blood pressure
• Prolactin level
• Mental state

Quinagolide selectively binds to D2 receptors expressed on the surface of lactotroph cells with high affinity which results in reduced adenylyl cyclase activity, reduced intracellular cyclic adenosine monophosphate and inhibited prolactin secretion.

Tablet 25μg

• Norprolac (Ferring) originator

Tablet 75μg

• Norprolac (Ferring) originator

Tablet 150μg

• Norprolac (Ferring) originator